Skip to main content

Table 2 Different categories of treatment for S2-013 cell line

From: Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo

# Group n Treatment
I control 15 -
II gemcitabine* 15 gemcitabine
III gemcitabine/CoPP 15 gemcitabine/CoPP
V gemcitabine/DFO 15 gemcitabine/DFO
IV gemcitabine/ZnPP 15 gemcitabine/ZnPP
  1. * Gemcitabine (4 doses, 60 mg/kg per dose) on days 7, 10, 13 and 17.
  2. CoPP, ZnPP (5 mg/kg per dose) or biliverdin (50 μmol/kg per dose) every alternative day from day 5 to day 17.
  3. DFO administration via an intraperitoneal osmotic pump (250 mg/kg per day for two weeks) from day 7 onwards.